| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4188743 | Psiquiatría Biológica | 2007 | 11 Pages |
Abstract
Atomoxetine is a noradrenaline reuptake inhibitor that is being studied for use in the treatment of attention-deficit/hyperactivity disorder (ADHD) in Spain. To date, a variety of open-label, randomized, double-blind, placebo-controlled trials in children, adolescents and adults have been published. We present the pharmacological properties and indications of atomoxetine and discuss published evidence on its efficacy in ADHD and comorbid disorders. The adverse effects profile and safety concerns of this drug are critically reviewed.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Psychiatry and Mental Health
Authors
MarÃa Teresa de Lucas Taracena, Francisco Montañés Rada,